Nature's Ultra-Stable Cyclic Peptides as Frameworks for Designing New Drugs

This is a review article surveying current trends in peptide-based pharmaceuticals, with a focus on naturally occurring cyclic disulfide-rich peptide scaffolds. The authors describe the structural and pharmaceutical properties of these scaffolds and review grafting and engineering strategies used to create drug candidates.

A major challenge in drug development is that many disease-causing proteins are considered 'undruggable' because small molecule drugs are too simple to bind them effectively, while antibodies are too large to reach intracellular targets. Cyclic disulfide-rich peptides bridge this gap — they are large and structured enough to bind complex protein surfaces, yet small and stable enough to potentially survive oral delivery and enter cells. This review outlines a roadmap for using nature's own molecular engineering to solve this problem.

This review comes from David Craik's laboratory, one of the pioneering groups in cyclotide (cyclic peptide) research. The concept of using stable natural peptide frameworks as drug scaffolds has grown into a major branch of pharmaceutical research, influencing companies developing cyclic peptide therapeutics for cancer, pain, cardiovascular disease, and infectious disease. The approach represents a middle ground between traditional small molecule drugs and large biologics, potentially combining the best properties of both.

As a review from 2014, it captures the state of the field at that time and may not reflect more recent advances in cyclic peptide synthesis, delivery, and clinical development. The review focuses on the theoretical promise of these scaffolds, and the abstract does not detail specific clinical successes or failures. The actual translation of grafted cyclic peptides into approved drugs remains an ongoing challenge. Oral bioavailability and cell permeability, while theoretically improved, have been difficult to achieve consistently in practice.